Positioning biologics and new therapies in the management of inflammatory bowel diseaseHonap, Sailish; Cunningham, Georgina; Tamilarasan, Aravind Gokul; Irving, Peter M.Current Opinion in Gastroenterology: July 2019 - Volume 35 - Issue 4 - p 296–301 doi: 10.1097/MOG.0000000000000546 INFLAMMATORY BOWEL DISEASE: Edited by Miguel Regueiro Buy Abstract Author InformationAuthors Article MetricsMetrics Purpose of review Since the advent of anti-tumour necrosis factor agents, knowledge of their optimal use and their pitfalls has grown exponentially. However, the range of therapeutic agents available to clinicians and patients is expanding, creating challenging decisions about which drugs to use at any given time point. The present review aims to provide a framework within which positioning decisions can be made in the context of limited comparative effectiveness data. Recent findings The present review will summarize the current literature emphasizing how best to use biologic agents, and will provide suggestions as to how they should be positioned. Recent trials comparing efficacy and safety will be considered as will their strengths and weaknesses. Summary On reading this review, clinicians should have an understanding of the optimal use of currently approved biologic agents and tofacitinib and how they might be positioned in relation to one another. IBD Centre, Guy's and St. Thomas’ Hospitals NHS Foundation Trust, London, UK Correspondence to Peter M. Irving, Department of Gastroenterology, Guy's and St. Thomas’ Hospitals NHS Foundation Trust, IBD Centre, First Floor College House, South Wing, St Thomas's Hospital, Westminster Bridge Road, London SE1 7EH, UK. Tel: +44(0)2071881222; fax: +44(0)2071882484; e-mail: email@example.com Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.